Despite clear evidence that each ovarian cancer subtype has distinct molecular profiles and ER expression patterns [22], endocrine therapy has primarily been investigated in small Phase I and II trials involving heavily pretreated patients and mixed histological subtypes [12,18]. The gene discussed is ESR1; the disease is ovarian cancer.